Barring some previous bad relationship between Nader and someone at the FDA, the only thing that seems to make sense re: the juvenile, emotional, and extremely negative tone of individuals at the FDA (as revealed in the emails) re: Leronlimab is fear.

If these FDA individuals see their current funding or employment future (or potential future) being dependent on the success of Pfizer, J&J, and other big pharmas - companies that stand to lose lots of market share from a drug that actually IS safe and effective -

Then that would explain why they tried to bench us before we got up to bat. Imagine a former FDA employee during his BP hiring interview . . . when he tells the interviewer how it was HIS decision to bury Leronlimab. That might even be worth a hiring bonus.

When I first invested in CYDY in March 2020, I remember discussing this very topic with my son; our molecule sounded so incredibly promising, I wondered what other big pharmas would do to keep their market share, saving lives be damned. The BP Covid "vax" response told me everything I needed to know about how much Pfizer and etc cared about human life.

75 years for Pfizer to release their trial data?
Right.